Atopic Dermatitis Highlights From AAD 2022

Lindsay C. Strowd, MD


April 18, 2022

Dr Lindsay Strowd, from the Wake Forest School of Medicine, Winston-Salem, North Carolina, reports on key findings on atopic dermatitis (AD) presented at the American Academy of Dermatology 2022 Annual Meeting.

First, she discusses updates to the clinical guidelines that address comorbidities linked with AD. On this theme, Dr Strowd presents a study that found associations between AD and delinquent behavior in children and another study linking long-term sleep issues in adults with severe AD.

Next, Dr Strowd analyzes two studies that looked at patients treated with dupilumab. The first, a retrospective cohort study across 12 locations in Canada, supports recommendations that individuals with AD should not discontinue therapy because of fear of contracting COVID-19. The second, a single-arm, observational study, assessed whether dupilumab in patients with moderate to severe AD decreased concomitant therapies.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.